Immunotherapy plus chemo shows promise in Tough-to-Treat mesothelioma
Disease control
Completed
This study tested whether adding the immunotherapy drug durvalumab to standard chemotherapy helps people with advanced pleural mesothelioma live longer. The trial included 214 adults whose cancer could not be removed with surgery. Participants received either durvalumab plus chem…
Phase: PHASE3 • Sponsor: PrECOG, LLC. • Aim: Disease control
Last updated May 17, 2026 06:52 UTC